LLY
Eli Lilly and Company
LLY has the edge over XRAY overall, supported by stronger fundamentals and stronger modeled upside.
XRAY
DENTSPLY SIRONA Inc.
XRAY trails on the overall score without a compensating advantage in the available component scores.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
XRAY Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Weak |
XRAY's cash flow is currently healthy, and its revenue and profitability are stable, but its balance sheet is weak.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
XRAY PE Valuation
XRAY has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over XRAY on the outlook, with more favorable earnings and revenue expectations.
XRAY Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Stable | |
| Stable | |
| Limited | |
| Low |
Analysts expect XRAY's earnings, revenue and profitability to hold roughly steady. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over XRAY on earnings quality, reporting a profit while its opponent remains loss making.
XRAY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.26 | — |
| Q3 2026 | -$0.62 | +$3.73 |
| Q2 2026 | -$2.75 | +$1.92 |
| Q1 2026 | -$3.15 | +$1.32 |
| Q4 2025 | -$3.00 | +$1.48 |
| Q3 2025 | -$4.35 | -$2.28 |
| Q2 2025 | -$4.67 | -$3.81 |
| Q1 2025 | -$4.47 | -$4.03 |
| Q4 2024 | -$4.48 | -$3.86 |
XRAY is still losing money, but far less than before: $0.62 per share over the past year, against $4.82 at its worst in early 2023.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over XRAY on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over XRAY on profitability, with a higher operating margin.
XRAY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $836M | -7.5% |
| Q2 2026 | $898M | -4.1% |
| Q1 2026 | $880M | +0.1% |
| Q4 2025 | $961M | +6.2% |
| Q3 2025 | $904M | -4.9% |
| Q2 2025 | $936M | -4.9% |
| Q1 2025 | $879M | -7.8% |
| Q4 2024 | $905M | -11% |
XRAY's revenue fell from its 2019 peak and has held roughly level since: $836M last quarter, down 7.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 4.4% | +29 points |
| Q2 2026 | 9.1% | +23 points |
| Q1 2026 | -4% | -11 points |
| Q4 2025 | -14% | +42 points |
| Q3 2025 | -24% | +25 points |
| Q2 2025 | -14% | -19 points |
| Q1 2025 | 7.2% | +2.8 points |
| Q4 2024 | -56% | -64 points |
XRAY's operating margin was 4.4% last quarter, up 29 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over XRAY on cash flow, with more consistent year-over-year improvement.
XRAY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $0 | -100% |
| Q2 2026 | $55M | +244% |
| Q1 2026 | -$12M | $0 |
| Q4 2025 | $60M | +67% |
| Q3 2025 | $40M | -59% |
| Q2 2025 | $16M | -90% |
| Q1 2025 | -$12M | -$3M |
| Q4 2024 | $36M | -70% |
XRAY still generates free cash flow, though less than at its 2019 peak: $103M over the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over XRAY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
XRAY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.6% | -1.3M shares |
| 1 year | -0.2% | -300K shares |
| 3 years | -5.9% | -12.6M shares |
| 5 years | -9.7% | -21.3M shares |
| Available history | -11% | -25.2M shares |
XRAY has 199M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $13M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q4 2024 | — |
| Q3 2024 | $100M |
| Q2 2024 | $150M |
| Q1 2024 | — |
| Q4 2023 | $150M |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over XRAY on leverage, with a lower net debt burden relative to earnings.
XRAY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 7.1x | High |
| Q2 2026 | 50.9x | High |
| Q3 2024 | 39.2x | High |
| Q2 2024 | 6.6x | High |
| Q1 2024 | 5.9x | High |
| Q4 2023 | 6.9x | High |
| Q3 2023 | 6.9x | High |
| Q2 2022 | 1.9x | Healthy |
XRAY's net debt is about 7.1 years of its operating earnings (EBITDA), up from 5.9 years a year ago.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
XRAY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.7 | Neutral |
| Stochastic | 22.9 | Neutral |
XRAY's weekly RSI is 41 (neutral) and its Stochastic is 23 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
XRAY PE vs Healthcare Sector
| Metric | XRAY | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
XRAY has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over XRAY on trend strength, trading above more of its moving averages.
XRAY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.14 | 1.1% above |
| 20 week MA | $10.7 | 14% below |
| 50 week MA | $11.3 | 18% below |
| 100 week MA | $13.2 | 30% below |
| 200 week MA | $22.7 | 59% below |
XRAY has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 59% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over XRAY on returns for 2026, with the stronger performance.
XRAY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $56.8 | $51.8 | -8.8% |
| 2021 | $51.8 | $55.4 | +7% |
| 2022 | $55.4 | $31.8 | -43% |
| 2023 | $31.8 | $35.6 | +12% |
| 2024 | $35.6 | $18.9 | -47% |
| 2025 | $18.9 | $11.5 | -39% |
| 2026 YTD | $11.5 | $9.24 | -20% |
XRAY has finished lower in four of the last six years. It's down 20% so far in 2026.